相关临床试验
3
0 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
1847
已完成
1
33.3%
Unknown
2
66.7%
- Expert hematopathology second-opinion review changes guideline-directed management in roughly 1 of every 5 cases compared with community-based review, highlighting a critical diagnostic precision gap in hematologic malignancies. - Matthew Matasar, MD, argues that AI-assisted digital pathology is the "here and now" for hematologic malignancy, where diagnostic accuracy is both critical to outcomes and notoriously heterogeneous. - Arturo Loaiza-Bonilla, MD, calls for a shared governance "commons" to standardize AI implementation across health systems, rather than each institution building isolated frameworks. - Both experts agree that AI is already reshaping drug discovery, citing the first AI-designed molecule now in a phase 3 trial for pulmonary fibrosis.
- With the CDC largely silent this fall, the American Medical Association and the University of Minnesota's Vaccine Integrity Project published independent reviews in JAMA to guide flu, Covid-19, and RSV immunization. - New recommendations from the AAP, AAFP, ACOG, and IDSA advise RSV immunization for high-risk adults 50+, everyone over 75, pregnant people, and infants, plus annual flu shots for everyone 6 months and older. - Updated Covid-19 vaccines targeting the XFG Omicron subvariant are recommended for adults, with a second dose six months later for those 65 and older, and insurers have indicated coverage without cost sharing. - The first mRNA flu vaccine is newly available for adults 50 and older, while ACOG extended the maternal RSV vaccine window through March 1 due to a later, more severe RSV season.
- Five Republican members of Congress have urged CMS to reverse a roughly 75% Medicare payment cut for image-guided superficial radiation therapy used in office-based skin cancer treatment. - The payment cut, which took effect January 1, has led more than 160 dermatology practices to discontinue the therapy, potentially pushing rural patients toward less-accessible urban cancer centers. - The dispute highlights an ongoing conflict between dermatologists and radiation oncologists over appropriate use and reimbursement, with CMS and the AMA siding with radiation oncologists. - CMS has stated it remains open to hearing feedback on the effect of final policies for consideration in potential future rulemaking.
- The Department of Health and Human Services will not finalize a proposed rule that would have blocked all Medicaid and Medicare funding for hospitals providing pediatric gender-affirming care, according to a document obtained by NPR. - The proposed rule, issued in December and drawing more than 30,000 public comments, was opposed by the American Medical Association and the Children's Hospital Association, which urged its withdrawal. - Legal experts called the unprecedented "conditions of participation" rule unlawful, noting it would have violated the Medicare Act by using federal funding to control the practice of medicine. - Separately, Medicaid and CHIP will stop paying for gender-affirming surgeries and hormone treatments for transgender minors effective Oct. 13, while continuing mental health coverage.
- AI is forcing medical schools to rapidly reconsider physician training, with educators describing this as a "key inflection point for medical education," according to NYU's Marc Triola. - New AI tools enable personalized assessment of trainees' communication and clinical reasoning skills, areas that have long been difficult to evaluate directly. - Concerns about "never-skilling" and "deskilling" arise as trainees offload cognitive tasks to AI, though some experts argue not all deskilling is harmful and may free capacity for essential skills. - Medical education leaders emphasize the need for adaptive training models that partner with learners, as the evidence base on AI's educational effects remains surprisingly limited.
- Prior authorization requirements can delay care and worsen health conditions for patients with neurological diseases such as epilepsy and Parkinson's disease, according to a JAMA Neurology study. - Nearly half of insured adults report having care denied or delayed due to prior authorization requirements, per a KFF survey. - Starting in 2027, certain health insurers will be required to implement electronic prior authorization submission systems to speed up the process. - More than 83% of prior authorization appeals resulted in insurers partially or fully overturning the initial denial in 2022, according to the AMA.
- CMS proposed a new rule requiring payers to respond to urgent drug prior authorization requests within 24 hours, expedited within 72 hours, and standard within 7 days, with compliance by October 2027. - An industry pledge led by AHIP reportedly reduced prior authorizations by 11%, but only 33% of physicians surveyed by the AMA believe it will make a meaningful difference. - The American College of Rheumatology supports the CMS rule but urges further detail on denial reasons, specialty-level reporting, and extension to Medicare Part D and state-based exchanges. - A 2025 Commonwealth Fund analysis found 21% of working-age adults with private insurance were denied physician-recommended care, with 41% experiencing delayed care as a result.
- Utah became the first state to allow an AI chatbot called Doctronic to refill prescriptions without a doctor visit, launching in January 2026 under a regulatory sandbox program. - The state's medical licensing board was not informed before launch and has called for the program to be halted, citing risks of automatically renewing medications like blood thinners. - Doctronic's AI matched human doctor diagnoses 80% of the time in a company-led study, but no peer-reviewed data on prescription refill safety has been published. - The FDA has taken a hands-off approach, while other states including Texas and Wyoming are also waiving rules for AI in healthcare.
- The Israel Medical Association published a position paper establishing principles for integrating AI into clinical settings, emphasizing that AI systems must support rather than replace physician decision-making. - The American Medical Association adopted new policies calling for mandatory physician oversight, transparency, and accountability whenever AI is used in patient care or health insurance decisions. - Both organizations warn that AI risks include biased training data, false sense of security, hallucinations, and the erosion of the doctor-patient relationship if human context is sidelined. - The AMA is advocating for regular audits of AI-driven clinical review tools and full disclosure when AI influences prior authorization or coverage determinations.
- The healthcare AI market has focused on speeding up prior authorization submissions, but denial rates remain high and 88% of denials go unchallenged despite an 80.7% overturn rate on appeal. - Physicians spend 13 hours weekly on prior authorizations, and 78% report that delays cause patients to abandon treatment, contributing to burnout and adverse events. - A shift from reactive denial management to proactive, AI-driven validation at the point of entry can prevent denials before they occur and identify missed revenue opportunities. - Next-generation AI must reason across clinical documentation and payer policies at submission and close the feedback loop by learning from denial outcomes to continuously improve.
